GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Tuesday

GT Biopharma (NASDAQ:GTBP) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($1.55) per share for the quarter.

GT Biopharma Stock Performance

Shares of GT Biopharma stock opened at $2.40 on Tuesday. GT Biopharma has a twelve month low of $1.72 and a twelve month high of $10.66. The firm has a market cap of $6.09 million, a P/E ratio of -0.34 and a beta of 0.59. The firm’s 50-day simple moving average is $2.31 and its 200-day simple moving average is $2.49.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GTBP shares. Roth Capital upgraded GT Biopharma to a “strong-buy” rating in a research note on Monday, December 2nd. Roth Mkm started coverage on GT Biopharma in a research note on Monday, December 2nd. They set a “buy” rating and a $11.00 price objective for the company.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.